$AKBA 1. current market cap $76.54m 2. Cash $175m 3. One approved drug with annual sale of $170m 4. Another drug approved Japan and waiting for approval in Europe. And is currently seeking a path forward with FDA. 5. ARDS trial results expecTed this quarter. 6. partnerships with Otsuka and Vifor. If this is not the most undervalued stock in the whole universe, then I don’t know if there is a universe.